Montelukast 6–14-Vuotiaille Pediatrisille Potilaille Accord

Montelukast, the active ingredient in Montelukast 6–14-Vuotiaille Pediatrisille Potilaille Accord, is a leukotriene receptor antagonist presented as an oral dosage form for oral use. It is used to manage asthma and allergic rhinitis in children aged 6 to 14 years. GNH USA supplies Montelukast 6–14-Vuotiaille Pediatrisille Potilaille Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast is a leukotriene receptor antagonist indicated for respiratory allergic conditions. - Asthma: improves long‑term control and reduces the frequency of bronchospasm in pediatric patients. - Allergic rhinitis: relieves nasal congestion, sneezing, and itching caused by seasonal or perennial allergens. - Exercise‑induced bronchoconstriction: prevents airway narrowing triggered by physical activity in children.

Montelukast is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate pain often reported. - Abdominal pain: discomfort or cramps in the stomach area. - Nausea: feeling of queasiness without vomiting. - Cough: occasional dry cough. - Dizziness: transient light‑headedness. - Fatigue: unusual tiredness or lack of energy.

Serious or Rare Side Effects: - Allergic reactions: rash, urticaria, or angioedema. - Neuropsychiatric events: mood changes, anxiety, or suicidal thoughts. - Hepatic enzyme elevation: abnormal liver function tests. - Hematologic effects: neutropenia or eosinophilia. - Stevens‑Johnson syndrome: severe skin blistering. - Anaphylaxis: rapid, life‑threatening allergic response.

Before prescribing Montelukast, clinicians should consider several safety aspects. - Assess asthma control: ensure baseline therapy is optimized. - Monitor neuropsychiatric symptoms: watch for mood changes or suicidal ideation. - Use caution in hepatic impairment: adjust therapy if liver disease is present. - Avoid in patients with known hypersensitivity to montelukast or any component of the formulation. - Review concomitant medications: consider potential interactions. - Store at room temperature: keep in the original pack, protect from moisture.

Montelukast may interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir): may increase montelukast plasma levels. - CYP3A4 inducers (e.g., phenobarbital, rifampicin): may lower therapeutic concentrations.

Moderate Interactions (Monitor Closely): - Warfarin: monitor INR as montelukast can affect anticoagulation. - Other leukotriene modifiers (e.g., zafirlukast): additive effects may increase risk of side effects. - Beta‑agonists: no direct pharmacokinetic interaction, but clinical response should be observed.